Cancer Trial Results
The POLO Trial is Great, But Probably Not Practice-Changing
FORCE Blog | New PARP Inhibitor Approval for Pancreatic Cancer
Cancers | Free Full-Text | Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
HCP's Thoughts On Pancreatic Cancer | Knowledge | CREATION.co
Dr Amol Akhade on Twitter: "19 vs 19.2 . POLO . Metastatic pancrease ca. Once again Placebo arm has longer OS than Olaparib. I really appreciate the positive spin off by medical
Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
Cancer Trial Results
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink
Olaparib for Pancreatic Cancer with BRCA Mutations - NCI
Olaparib now approved for advanced pancreatic cancer - UChicago Medicine
Cureus | Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer | Article
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
POLO Trial Shows Maintenance Olaparib Improves PFS in Metastatic Pancreatic Cancer - The ASCO Post
JNCCN study evaluates cost-effectiveness of o | EurekAlert!
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
ASCO GI 2021: Results From the Phase 3 POLO Trial
Olaparib in Pancreas Cancer | Polo Trial | One oncologist breaks it down - YouTube
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Phase III POLO Trial - Slideset Download - Clin Onc June 2019 | CCO
Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
